evipedia.ai
← Back

Bhringaraj for Hair Growth

Evidence Review created on 09/19/2026 using AI4L / Opus 5

Also known as: Eclipta alba, Eclipta prostrata, Eclipta erecta, Ecliptae Herba, Bhringraj, Bhringaraja, Bhrungaraj, Kesharaja, False Daisy, Trailing Eclipta, Yerba de Tago, Han Lian Cao, Mo Han Lian, Karisalankanni, Maka, Kesuti

Motivation

Bhringaraj (Eclipta alba) is a small, sprawling herb of the daisy family that grows in wet ground across India, Nepal, southern China and much of tropical Asia. Classical Ayurvedic texts name it kesharaja, the ruler of hair, and its leaves — pressed into a warm oil or ground into a paste — have been worked into the scalp for centuries to thicken hair and hold its colour. It is now sold worldwide as a scalp oil, a loose powder and an oral capsule.

Attention beyond tradition comes from laboratory work. Extracts of the plant push resting hair follicles in animals back into their growing phase, and the herb’s signature compound also shields the liver from chemical injury in the same models. Hair thinning itself matters beyond appearance, because it often tracks iron stores, thyroid function and long-running stress.

This review examines what is established about bhringaraj and hair: the size and quality of the human evidence, what animal and cell work can and cannot settle, how the herb is prepared and applied, where it collides with other treatments, and what can be measured to judge whether it is doing anything at all.

Benefits - Risks - Protocol - Conclusion

High-level overviews of bhringaraj and of Ayurvedic hair treatment that give context the primary trials do not.

No content from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io could be found. Searches of each platform by name and by domain returned nothing on bhringaraj or Eclipta; the herb sits outside the supplement territory those platforms cover, which is weighted toward compounds with Western clinical trial programmes.

Grokipedia

  • Eclipta prostrata

    Covers the botany, synonymy and traditional standing of the plant under its accepted binomial, and names bhringraj and yerba de tago as its common names.

Examine

  • Bhringaraj

    Grades the whole evidence base as one trial in 60 participants and is blunt that the hair claim rests on preliminary petroleum-ether-extract work, not on human outcomes.

ConsumerLab

No ConsumerLab article, product review or clinical update exists for bhringaraj. ConsumerLab’s testing programme is built around supplement categories with large US retail volume, and single-herb Ayurvedic scalp preparations have not been brought into it.

Systematic Reviews

Systematic reviews and meta-analyses covering the therapeutic category bhringaraj belongs to, and the principal risk that category carries.

No systematic review or meta-analysis addresses bhringaraj itself. The claimed effect is represented only at the level of the herbal and polyphenol classes it belongs to, and the principal risk only at the level of contact allergy in general; neither is represented by a bhringaraj-specific synthesis.

Mechanism of Action

Bhringaraj’s proposed action is on the follicle cycle rather than on hormones. Scalp hair alternates between anagen (the growing phase, lasting years), catagen (a short regression phase) and telogen (a resting phase before the shaft is shed). Pattern hair loss is a progressive shortening of anagen.

In shaved mice, Eclipta prostrata raised fibroblast growth factor 7 (FGF-7, a growth signal from the dermal papilla, the cell cluster at the follicle’s base) and lowered fibroblast growth factor 5 (FGF-5, the signal that ends anagen), while activating mTOR signalling (a nutrient-sensing pathway that licenses cell growth) in cultured human dermal papilla cells (Lee et al., 2019). Petroleum-ether extract also suppressed transforming growth factor beta 1 (TGF-β1, a brake that pushes follicles into regression) (Begum et al., 2015). Earlier mouse work traced the same shift through sonic hedgehog and bone morphogenetic protein 4 (developmental signals that switch follicles on and off) (Datta et al., 2009).

A competing explanation puts the action on 5α-reductase (the enzyme converting testosterone to dihydrotestosterone, the androgen that shrinks follicles) and on Wnt/β-catenin signalling (a pathway governing follicle regeneration) (Sadhu et al., 2026). Neither account has been demonstrated in human scalp.

Bhringaraj is a whole-plant botanical, not a single compound, so pharmacological parameters apply only to its marker constituent, wedelolactone. That coumestan is heavily glucuronidated and methylated by UGT1A1 and UGT1A9 (liver enzymes that attach sugar groups to compounds for excretion), giving low oral absorption; no human half-life is published (Li et al., 2016).

Historical Context & Evolution

Bhringaraj entered recorded medicine as a liver and bleeding remedy, not a cosmetic. Ayurvedic materia medica lists it for jaundice, enlarged liver, eye complaints and snakebite, and the same plant appears in Chinese practice as Han Lian Cao, paired with Ligustrum lucidum in the formula Er-Zhi-Wan for what that tradition frames as kidney depletion — a pairing still studied for bone loss (Cheng et al., 2011). Its hair reputation arrived separately: Ayurveda classifies hair fall as khalitya and premature greying as palitya, treats both as failures of scalp nourishment, and delivers remedies as taila, a herb-infused oil massaged in during shiro abhyanga. Bhringaraj became the anchor herb of those oils.

Modern interest dates to the mid-2000s, when Indian pharmacy groups tested solvent extracts on shaved rodents. Roy et al., 2008 reported that a petroleum-ether extract halved the time to regrowth initiation and produced more anagen follicles than 2% minoxidil; the same group had already reported a three-herb formulation cutting initiation time to a third (Roy et al., 2007). Those findings are frequently cited as though they settled the question. What they established is narrower: a reproducible effect on rodent coat cycling, on shaved normal skin, against a single low-strength comparator.

Opinion has since shifted twice. Mechanistic work through the 2010s made the follicle-cycle account concrete rather than speculative. In the other direction, systematic reviews of herbal hair-loss trials still find no bhringaraj entry to include (Allam et al., 2025), so its clinical standing has not moved with its laboratory standing.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the two randomized human trials — a multi-herb oil against active comparators with no placebo arm, and one small placebo-controlled oral trial that measured no hair endpoint — are each unreplicated single studies, and every remaining hair outcome comes from rodent models and cultured dermal papilla cells.

Medium 🟩 🟩

Lower Blood Pressure and Cholesterol from Oral Whole-Leaf Bhringaraj ⭕️ Not Central to Hair Growth

A placebo-controlled trial in 60 men with mild hypertension (persistently raised blood pressure) gave 3 g/day of dried leaf powder for 60 days. Mean arterial pressure, total cholesterol and low-density lipoprotein (the cholesterol fraction that drives arterial plaque) all fell, alongside higher urine output (Rangineni et al., 2007). This bears on cardiometabolic risk, not on hair: no hair endpoint was recorded. The trial is small, single-centre and unreplicated, so the effect size is provisional.

Magnitude: Mean arterial pressure fell 15%, total cholesterol 17%, low-density lipoprotein 24% and triglycerides 14% over 60 days on 3 g/day of dried leaf, with urine volume up 34%.

Low 🟩

Increased Hair Density, Thickness and Growth Rate with a Bhringaraj-Containing Ayurvedic Oil

A 120-day randomized, double-blind study applied Neeli Bhringadi oil — a multi-herb preparation containing bhringaraj — to the scalp (Patel et al., 2026), run by a contract research company serving the Ayurvedic product trade. Density, thickness and growth rate rose; with every arm active, the herb’s contribution is unresolved.

Magnitude: At Day 120 the oil-only arm reached 277.6 ± 33.7 hairs/cm², 16.56 ± 1.98 µm thickness and 290.3 ± 39.6 µm/day growth rate against its own baseline (p < 0.0001; the p-value is the probability of a difference this large arising by chance).

Reduced Premature Greying with a Bhringaraj-Containing Ayurvedic Oil ⭕️ Not Central to Hair Growth

The same 120-day study scored grey-hair severity and found it fell in the oil arm (Patel et al., 2026). This bears on hair colour, not growth. Bhringaraj is a traditional hair darkener, so cosmetic staining cannot be separated from true repigmentation here.

Magnitude: Greying Severity Score (a graded count of grey hairs in a marked scalp area) fell to 9.24 ± 3.28 at Day 120 against baseline (p < 0.0001); no placebo-adjusted figure exists.

Reduced Adherent Scalp Flaking ⭕️ Not Central to Hair Growth

Scalp flaking scores dropped over 120 days of oiling (Patel et al., 2026). This bears on scalp condition, not hair growth. Any occlusive oil softens and lifts adherent scale, so the effect is plausibly from the vehicle, and no vehicle-only arm existed.

Magnitude: Adherent Scalp Flaking Score fell to 8.08 ± 4.95 at Day 120 against baseline (p < 0.0001), with no vehicle-controlled comparison available.

Speculative 🟨

Faster Entry into the Hair Growth Phase

In shaved rats and mice, extracts halved the time to visible regrowth and raised the share of follicles in anagen (Roy et al., 2008). Basis is animal work only; no human cycle data exist.

Follicle Protection During Chemotherapy-Induced Hair Loss

A petroleum-ether extract cut follicle cell death in cyclophosphamide-treated mice by blocking the p53/Fas pathway (a cell-suicide signal) (Wang et al., 2024). Basis is animal and cell work only.

Liver Protection ⭕️ Not Central to Hair Growth

Rodent work and the marker compound wedelolactone blunt chemically induced liver injury (Ha et al., 2023). This bears on liver health, not hair. Basis is animal and cell work only.

Blood Glucose Lowering ⭕️ Not Central to Hair Growth

In diabetic rodents, extracts and the marker compound wedelolactone lowered blood glucose, with the mechanism unresolved (Timalsina & Devkota, 2021). This bears on metabolic health, not hair. Basis is animal and cell work only.

Benefit-Modifying Factors

  • Baseline iron stores: Ferritin below roughly 30 ng/mL sustains diffuse shedding regardless of what is applied to the scalp. Any regrowth signal is masked until iron is repleted, which is why low ferritin is the most common reason a topical looks inert.

  • Thyroid and vitamin D status: Both underactive and overactive thyroid produce diffuse loss that mimics pattern loss, and low vitamin D is associated with disordered follicle cycling. Correcting either changes the trajectory more than the herb plausibly can.

  • Androgen-pathway genetics: Variants in SRD5A2 (the gene for the enzyme making dihydrotestosterone) and androgen-receptor CAG repeat length set how androgen-driven the loss is. The mechanistic case for bhringaraj acting on this pathway is untested in humans, so benefit in strongly androgenic loss is unproven.

  • Sex-based differences: The single human hair study enrolled both sexes aged 18–55 without reporting a sex split, and the oral cardiovascular trial enrolled men only. No sex-specific efficacy estimate exists for either route of administration.

  • Age and stage of loss: Miniaturised follicles can still be pushed back toward anagen; scarred or fully lost follicles cannot. Adults at the older end of the target range carry a higher share of the latter, which caps the achievable response irrespective of agent.

  • Pre-existing scalp inflammation: Seborrheic dermatitis (flaking, inflamed scalp), psoriasis (thick scaly plaques) or folliculitis (inflamed follicles) shortens anagen independently. Untreated, inflammation reduces benefit and makes an irritant reaction to the oil harder to distinguish from the condition.

  • Preparation and marker content: Effects in rodents were largely confined to petroleum-ether extract. Commercial oils and powders vary widely in wedelolactone content and rarely state it, so two products carrying the same name are not interchangeable inputs.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: there is no replicated human adverse-event dataset for bhringaraj, only a single small oral trial, family-level patch-test case series, and contamination surveys of Ayurvedic products in general.

Medium 🟥 🟥

Blood Pressure Drop and Increased Fluid Loss with Oral Use

The only placebo-controlled human trial of oral bhringaraj ran in men with mild hypertension and reported a fall in mean arterial pressure with a rise in urine volume and urinary sodium (Rangineni et al., 2007). In someone with normal blood pressure, or on an antihypertensive (a blood-pressure-lowering medicine) or a diuretic (one that increases urine output), the same pharmacology reads as an adverse effect: lightheadedness on standing and greater fluid and sodium loss. It reversed on stopping. Topical use has not been shown to produce systemic exposure of this order.

Magnitude: Mean arterial pressure fell 15% and urine volume rose 34% over 60 days on 3 g/day of dried leaf in 60 mildly hypertensive men.

Heavy-Metal Contamination of Ayurvedic Bhringaraj Products

Bhringaraj is bought almost entirely as an Ayurvedic preparation, and that supply chain carries a documented lead, mercury and arsenic problem. A survey of Ayurvedic medicines sold online found detectable toxic metal in a fifth of products, from United States and Indian manufacturers alike (Saper et al., 2008). Clusters of clinical lead poisoning traced to Ayurvedic supplements have been reported since (Breeher et al., 2015). The risk attaches to the product rather than to the plant, and independent testing removes most of it.

Magnitude: 20.7% (95% confidence interval, the range the true value likely occupies: 15.2–27.1%) of 193 products contained detectable lead, mercury or arsenic, and every metal-positive product exceeded at least one acceptable daily intake limit.

Low 🟥

Allergic Contact Dermatitis to the Daisy Family

Bhringaraj is an Asteraceae (daisy family) plant, and sesquiterpene lactones (the family’s characteristic allergens) cause allergic contact dermatitis from herbal cosmetics (Punchihewa et al., 2022). No patch-test series has tested bhringaraj itself, so the signal is extrapolated from relatives; scalp and face are typical sites.

Magnitude: In a ten-year Australian patch-test series, 1.2% of 3,679 patients reacted to Compositae (the older name for the daisy family) allergens, and personal-care products accounted for roughly a third of the clinically relevant cases; no bhringaraj-specific rate exists.

Oil-Induced Acne and Folliculitis from Heavy Scalp Application

Bhringaraj is usually delivered in coconut or sesame oil left on the scalp for hours. Pore-blocking hair oils are a recognised cause of pomade acne along the hairline and of follicular pustules (Plewig et al., 1970). The evidence is descriptive case work on hair oils generally, not bhringaraj.

Magnitude: Not quantified in available studies. Pomade acne was characterised in descriptive case series without incidence denominators, and no controlled trial has measured the rate for any specific hair oil.

Speculative 🟨

Lowered Blood Glucose

Extracts reduce glucose in diabetic rodents by an unidentified mechanism (Timalsina & Devkota, 2021). No human glucose data exist, so any additive effect with glucose-lowering medication is inferred from animal work alone.

Oestrogen-Like Activity of the Coumestan Class

Wedelolactone is a coumestan, a class with oestrogen-receptor affinity. A formula containing the herb produced no uterine growth in rats (Cheng et al., 2011), so the concern rests on chemistry, not outcome data.

Competition for Liver Glucuronidation Enzymes

Wedelolactone is cleared mainly by UGT1A1 and UGT1A9, liver enzymes that attach sugar groups to compounds for excretion (Li et al., 2016). Sharing that route with medicines is an in-vitro inference, untested in people.

Risk-Modifying Factors

  • UGT1A1 variant status: People carrying the UGT1A1*28 variant (the Gilbert’s syndrome genotype, giving reduced activity of a liver clearance enzyme) clear wedelolactone more slowly, raising systemic exposure from oral dosing.

  • Glutathione S-transferase null genotypes: Absence of GSTM1 or GSTT1 (genes for enzymes that neutralise reactive chemicals) is associated with higher contact-sensitisation risk generally, which raises the chance of a reaction to a leave-on daisy-family preparation.

  • Baseline blood pressure and electrolytes: A resting systolic pressure already below 110 mmHg, or a serum potassium at the low end, makes the diuretic and pressure-lowering effect of oral dosing clinically meaningful rather than incidental.

  • Sex-based differences: The only oral safety data come from men. Women show roughly double the population rate of contact allergy, which shifts the topical risk profile upward without any bhringaraj-specific data to size it.

  • Pre-existing conditions: Known Asteraceae or ragweed sensitivity, active scalp dermatitis, liver disease, chronic kidney disease and pregnancy each amplify one of the identified risks. Diagnosed lead exposure from any source compounds the contamination risk.

  • Age: Adults at the older end of the target range more often take antihypertensives and diuretics, which is precisely where the oral pharmacology becomes additive, and their skin barrier is thinner, favouring irritant reactions.

Key Interactions & Contraindications

  • Antihypertensives and diuretics (amlodipine, lisinopril, losartan, hydrochlorothiazide, furosemide): Caution with oral use. Additive pressure and fluid loss can cause a symptomatic drop in blood pressure. Mitigation is holding or halving oral dosing and checking seated and standing pressure weekly for a month.

  • Glucose-lowering medication (metformin, glipizide, insulin): Monitor with oral use. Animal data suggest an additive glucose-lowering effect; the consequence would be hypoglycaemia (blood glucose falling too low). Mitigation is more frequent self-monitoring during the first four weeks of oral dosing.

  • UGT1A1 substrates with narrow margins (irinotecan, raltegravir, dolutegravir): Caution, theoretical. Shared glucuronidation could raise substrate levels and their toxicity. Mitigation is to avoid concurrent oral bhringaraj rather than attempt dose adjustment.

  • Topical minoxidil: No interaction identified; the trial arm combining both reported no additional adverse events. Mitigation for irritation is separating applications by several hours rather than layering the oil over freshly applied solution.

  • Over-the-counter anti-inflammatories (ibuprofen, naproxen) and decongestants (pseudoephedrine): Monitor. Both blunt or oppose the pressure and fluid effects seen with oral dosing, which can mask the change rather than prevent it. Mitigation is consistent blood-pressure recording.

  • Over-the-counter antifungal shampoos (ketoconazole, selenium sulfide, zinc pyrithione): Monitor. An occlusive oil layer reduces contact of the active with the scalp. Mitigation is timing separation: the medicated wash on oil-free days.

  • Other Asteraceae supplements (milk thistle, chamomile, echinacea, feverfew, arnica, dandelion): Caution. Shared sesquiterpene lactone allergens raise the chance of cross-sensitisation and of a reaction that is then misattributed. Mitigation is introducing only one family member at a time.

  • Supplements with additive blood-pressure lowering (beetroot nitrate, hibiscus, garlic extract, magnesium, potassium, fish oil): Caution with oral bhringaraj. Consequence is a compounded fall in blood pressure and, with potassium, electrolyte drift. Mitigation is staggering introductions by at least two weeks.

  • Other interventions: Microneedling and scalp injections: caution, since same-day oiling is a sensitisation route through breached skin; mitigation is a two-week washout. Permanent hair dye: monitor, as bhringaraj darkens hair and can shift the final shade; strand-test first.

Populations who should avoid Bhringaraj:

  • Pregnant and breastfeeding individuals, on both routes, given the coumestan content and the absence of any reproductive safety data
  • Anyone with known Asteraceae, ragweed, chrysanthemum or feverfew contact allergy, or a positive sesquiterpene lactone mix patch test
  • Chronic kidney disease at estimated glomerular filtration rate (a measure of kidney filtering capacity) below 30 mL/min/1.73 m², for oral use, because of the diuretic and sodium-losing effect
  • Child-Pugh Class B or C liver disease (moderate to severe cirrhosis), for oral use, because clearance depends on hepatic glucuronidation
  • Treated low blood pressure, or an untreated resting systolic pressure below 100 mmHg, for oral use
  • Children under 12, for whom no dosing or safety data exist on either route
  • Anyone with a blood lead level above 5 µg/dL from any source, until an independently tested product is sourced
  • Active scalp infection, open scalp wounds or scarring alopecia (hair loss in which the follicle itself is destroyed), for topical use

Risk Mitigation Strategies

  • Forty-eight-hour patch test before first scalp use: A coin-sized application of the finished oil to the inner forearm, read at 48 and 96 hours, catches most daisy-family contact allergy before it involves the whole scalp and face.

  • Certificate of analysis for lead, mercury and arsenic: Batch-level heavy-metal testing addresses the contamination risk a fifth of online Ayurvedic products carry. Preparations described as rasa shastra — herbs deliberately combined with metals — are excluded outright.

  • Topical-only start, oral added later if at all: Every identified systemic risk — pressure drop, fluid loss, glucose lowering, enzyme competition — belongs to oral dosing. Keeping to the scalp for the first three months removes them entirely.

  • Oral dose ceiling of 3 g/day of dried leaf for 60 days: That is the only dose and duration with human safety data behind it. Exceeding either takes the exposure outside anything that has been observed in people.

  • Shampoo out after one to two hours: Limiting contact time cuts the pore-blocking exposure that drives pomade acne and folliculitis, while retaining most of the claimed conditioning effect of the oil.

  • Weekly seated blood pressure for the first month of oral use: Catches the 15% mean arterial pressure fall before it produces symptoms on standing, particularly where an antihypertensive or diuretic is already in use.

  • Two-week washout before and after scalp procedures: Pausing the oil around microneedling, injections or transplantation prevents botanical exposure through breached skin, which is the main route to new sensitisation.

Therapeutic Protocol

  • Standard topical oil regimen: Bhringaraj-infused coconut or sesame oil, 5–10 mL, massaged into the scalp for five minutes and left one to two hours or overnight, two to three times weekly.

  • Powder paste alternative: Dried leaf powder, 10–20 g, mixed with water or yoghurt into a paste, applied to the scalp for 30–45 minutes and rinsed. Preferred where oily scalp makes leave-on oil impractical.

  • Oral whole-leaf approach: 3 g/day of dried leaf in divided capsules, the only orally tested amount, run for 60 days. Standardised extracts are marketed but carry no human dosing data.

  • Competing approaches presented without default: Conventional dermatology offers topical minoxidil and oral 5α-reductase inhibitors (drugs blocking that conversion), with large trial programmes. Ayurvedic practice offers oil and massage with thin clinical data. Neither framework’s evidence subsumes the other’s.

  • Sources behind each approach: The Neeli Bhringadi oil format comes from classical Kerala Ayurvedic texts and is what Patel et al., 2026 tested. The 3 g/day whole-leaf capsule regimen comes from Rangineni et al., 2007, the only oral trial.

  • Best time of day: Evening application dominates practice, so the oil can sit overnight and be washed out in the morning. There is no chronobiological evidence favouring any time; the reasoning is contact duration and practicality.

  • Half-life in the body: No human half-life has been published for bhringaraj or wedelolactone. Rat data show extensive glucuronidation and methylation with correspondingly low oral bioavailability (Li et al., 2016).

  • Single versus split oral dosing: The human trial used six 500 mg capsules in three divided doses. Splitting is the tested pattern and fits the rapid conjugation of the marker compound; no single-dose comparison exists.

  • Genetic polymorphisms affecting dose choice: UGT1A1*28 carriers clear wedelolactone more slowly and warrant the lower end of any oral range. SRD5A2 variants may predict whether androgen-pathway mechanisms are relevant at all, but no dosing rule follows.

  • Sex-based differences in dosing: The oral dose comes entirely from a male cohort. No female oral pharmacokinetic or dose-response data exist, so the same amount in women is an extrapolation rather than a tested figure.

  • Age-related adjustment: Adults at the older end of the target range are likelier to be on antihypertensives and to have reduced hepatic clearance, both arguing for topical-only use or the lowest oral amount with pressure monitoring.

  • Baseline biomarkers influencing response: Response is interpretable only once ferritin, thyroid-stimulating hormone and 25-hydroxyvitamin D sit in range. A deficiency in any of the three suppresses regrowth regardless of what is applied.

  • Pre-existing conditions influencing response: Scarring alopecia will not respond to any follicle-cycling agent. Practice controls active seborrheic dermatitis first, because inflammation shortens anagen independently and confounds any assessment.

Discontinuation & Cycling

  • Lifelong versus finite use: Ayurvedic practice frames topical use as an indefinite grooming habit, not a course. Oral use has human safety data only to 60 days, making it a defined block rather than an ongoing regimen.

  • Withdrawal effects: None documented for either route. No rebound shedding has been reported on stopping, and the cardiovascular changes in the oral trial were described as reversing once dosing ended.

  • Tapering: Not applicable. Neither route produces dependence or a withdrawal syndrome, and no tapering schedule appears in the trial literature or in classical practice.

  • Loss of effect on stopping topical use: Any follicle-cycle effect depends on continued exposure, as it does with conventional topicals. Hair gained during use would be expected to shed over the following cycle once application stops.

  • Cycling: No efficacy-preserving rationale exists for cycling topical use. For oral use, repeating the 60-day block after a break of equal length keeps exposure inside the only tested window while allowing biomarkers to be rechecked.

Sourcing and Quality

  • Species identity: An identified product names Eclipta alba or Eclipta prostrata explicitly on the label. Wedelia and Sphagneticola species share the marker compound and the market, and Mikania micrantha is used as a regional substitute for bhringaraj.

  • Marker standardisation: Wedelolactone content is the only meaningful potency measure and is almost never declared. Where a supplier states a percentage and will supply the assay method, batch-to-batch consistency can at least be checked.

  • Heavy-metal testing: Batch-level lead, mercury and arsenic results by inductively coupled plasma mass spectrometry (a trace-element assay) are the single most important document, given that a fifth of online Ayurvedic products carry detectable metal.

  • Third-party certification: United States Pharmacopeia verification, NSF International certification (an independent product-testing body) or an equivalent audit indicates identity and contaminant testing beyond the manufacturer’s claim. Good Manufacturing Practice claims alone proved a weak signal in the contamination survey (Saper et al., 2008).

  • Carrier oil quality: For infused oils, the carrier is most of the product. Cold-pressed coconut or sesame oil with a stated pressing date resists the rancidity that turns a conditioning oil into an irritant.

  • Reputable suppliers: Banyan Botanicals, Himalaya Wellness and Kerala-based classical taila manufacturers such as Kottakkal Arya Vaidya Sala are the established sources; the first supplied the blend used in a registered university protocol.

  • Formulation choice: Loose powder allows visual inspection and paste use but oxidises quickly; bottled infused oil is convenient but hides the raw material; capsules are the least verifiable form and the one where contamination surveys found the most metal.

Practical Considerations

  • Time to effect: The hair cycle sets the floor. The trial measured at 120 days, and standardised photographs are unreliable before four months on any agent. Reports of change within weeks reflect conditioning and shine, not growth.

  • Common pitfalls: Judging response before four months; using a product with no declared species or marker content; leaving heavy oil on indefinitely and causing hairline acne; and running oral dosing while on an antihypertensive without monitoring pressure.

  • A second common pitfall: Treating bhringaraj as a substitute for correcting ferritin, thyroid or vitamin D status. Where one of those is the actual driver, no topical will register, and the herb takes the blame for an unaddressed deficiency.

  • Regulatory status: In the United States it is a dietary supplement under the Dietary Supplement Health and Education Act, sold without Food and Drug Administration pre-approval for efficacy. In India, classical preparations fall under the Ministry of Ayush.

  • Regulator’s own stake: The Ministry of Ayush is mandated to promote Ayurveda as well as regulate it, so its assessments of Ayurvedic hair preparations carry an institutional interest in the conclusion and are better weighed alongside independent testing than in place of it.

  • Cost and accessibility: Neither expensive nor hard to obtain. Infused oil runs roughly 10–25 US dollars for a two-to-three-month supply and is stocked by Indian grocers and mainstream online retailers, putting it below generic minoxidil on cost.

  • Payer incentives: Insurers and national health systems treat pattern hair loss as cosmetic almost everywhere, so no institutional payer has a stake in favouring a botanical over a drug or the reverse. Commercial sponsorship, not payer bias, is the distortion to watch.

Interaction with Foundational Habits

  • Sleep: Indirect and mostly practical. Overnight oiling is the dominant application pattern and requires a towel or cap, which some find disruptive. No sedative or stimulant constituent has been identified, and the oral trial reported no sleep-related adverse events. Evening application otherwise sits neutrally against sleep.

  • Nutrition: Indirect and important. Iron, protein, zinc and vitamin D availability set the ceiling on any regrowth, so a botanical layered onto restricted intake produces nothing measurable. Poorly absorbed wedelolactone may benefit from co-ingestion with fat at oral dosing, by analogy with other fat-soluble plant compounds.

  • Exercise: Indirect, with one practical conflict. Nothing suggests bhringaraj blunts training adaptation. Heavy scalp oil plus sweat aggravates the pore-blocking risk, so the practical pattern is application after training rather than before, with the oil washed out before a long session.

  • Stress management: Indirect, potentially potentiating. Chronic stress pushes follicles prematurely into the resting phase, which is the same lever the herb is proposed to act on. Scalp massage, the traditional delivery method, is itself a calming, rest-and-digest stimulus, so the ritual may contribute independently of the plant.

Monitoring Protocol & Defining Success

Before starting, the useful baseline is the set of measures that explain hair loss independently of any herb: ferritin, 25-hydroxyvitamin D, thyroid-stimulating hormone and a complete blood count. Liver enzymes and a venous blood lead level belong in the baseline wherever an oral Ayurvedic preparation is used, because that supply chain carries a documented metal burden. A seated blood pressure reading and a standardised scalp photograph at a marked, reproducible site complete the picture; without a fixed imaging point, later comparisons are not interpretable.

Ongoing measurement follows the hair cycle rather than convenience. Imaging and shedding counts repeat at four and eight months. Blood pressure is checked weekly for the first month of any oral dosing and monthly after that. Liver enzymes and lead repeat at three months and then every six to twelve months while oral use continues. Topical-only use needs no routine blood work beyond the baseline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum ferritin (the iron storage protein) 70–100 ng/mL in women, 100–150 ng/mL in men Low iron stores sustain shedding and mask any regrowth Conventional labs call 15 ng/mL normal. Ferritin rises with inflammation, so pair with CRP (C-reactive protein, a general inflammation marker)
25-hydroxyvitamin D 40–60 ng/mL Deficiency is associated with disordered follicle cycling Conventional sufficiency starts at 30 ng/mL. No fasting needed, any time of day
TSH 0.5–2.0 mIU/L Both under- and overactive thyroid cause diffuse loss that mimics pattern loss TSH is thyroid-stimulating hormone, the pituitary signal that drives the thyroid. Conventional range runs to 4.5 mIU/L. Draw early morning fasting, paired with free T4 (the main circulating thyroid hormone)
Seated blood pressure 110–125 / 70–80 mmHg Oral bhringaraj lowers mean arterial pressure and raises urine output Not a blood test. Measure after five minutes seated, same arm, same time of day, adding a standing reading if lightheadedness appears
ALT and AST ALT 10–26 U/L, AST 10–26 U/L Detects liver injury from a herbal preparation or from metal contamination ALT is alanine aminotransferase and AST aspartate aminotransferase, liver enzymes released when liver cells are damaged. Conventional upper limits reach 40–50 U/L. Fasting preferred; pair with GGT (gamma-glutamyl transferase, a bile-duct enzyme)
Venous blood lead Below 1.0 µg/dL; no threshold is considered safe Ayurvedic preparations carry a documented lead burden Venous draw, not capillary. Add mercury and arsenic where the product is a rasa shastra preparation (one deliberately combining herbs with minerals and metals)
Serum potassium and sodium Potassium 4.0–4.5 mmol/L, sodium 138–142 mmol/L Oral use increases urinary sodium loss Conventional ranges are wider (potassium 3.5–5.2 mmol/L). Only needed if oral dosing runs past eight weeks or a diuretic is co-used
Hair density by trichoscopy (magnified scalp imaging) No established target exists; track change from the individual’s own baseline at a marked scalp point The only direct readout of whether anything is happening Same device, site and lighting each time. Four-month minimum interval, because the hair cycle is slow

Qualitative markers worth tracking alongside the numbers:

  • Hairs recovered from a standard 60-stroke comb on a fixed day of the week
  • Scalp comfort: itch, burning, tightness or stinging after application
  • Hair texture, shine and manageability, which change long before density does
  • Side-by-side photographic impression under identical lighting and parting
  • Lightheadedness on standing, as an early signal of the pressure and fluid effect during oral use
  • Energy levels and sleep quality, which track the nutritional and thyroid factors that drive shedding

Emerging Research

  • Registered trial of Chinese herbal oral and topical products: A six-month randomized, double-blind, placebo-controlled trial in 152 adults with hair loss and premature greying, measuring shedding counts, density and grey-hair index at weeks 12 and 24 (NCT06998680). The sponsor does not disclose the formulation, so bhringaraj content is unknown.

  • The only registered trial naming the species was withdrawn: A University of California, Davis protocol testing an oral blend of Eclipta alba, Emblica officinalis, Centella asiatica and Hibiscus sabdariffa in women with self-perceived hair loss never enrolled a participant (NCT05019066). The registry gap, not a negative result, is the finding.

  • Mechanistic work that could strengthen the case: A 2026 pharmacology review places the species among plants acting on 5α-reductase and Wnt/β-catenin signalling (Sadhu et al., 2026). Demonstrating either target in human scalp tissue would move the herb beyond traditional standing.

  • Chemotherapy-induced hair loss as a separate line: Mouse work implicating the p53/Fas cell-death pathway points toward a protective rather than growth-promoting use (Wang et al., 2024). A human trial there would test a different claim from the traditional one.

  • Evidence that could weaken the case: A 2026 meta-analysis of 32 polyphenol trials found no advantage over minoxidil on total hair count (El Ammari et al., 2026), and a 2025 systematic review of 16 herbal hair-loss trials included none testing bhringaraj (Allam et al., 2025).

  • Standardisation as the rate-limiting step: The marker compound is poorly absorbed and heavily conjugated in the liver (Li et al., 2016). Until products declare its content, trials cannot be compared and a null result cannot be separated from an underdosed product.

Conclusion

Bhringaraj is a daisy-family herb with a long and specific place in Indian hair care, delivered mainly as a scalp oil and occasionally as an oral preparation. Its case rests on two unequal bodies of work. In rodents and in cultured cells from the base of the hair follicle, extracts reliably shorten the resting phase and lengthen the growing phase, and the signalling behind that shift has been mapped in some detail. In people, the picture is far thinner: one randomized study of a multi-herb oil in which the plant is one named ingredient, with no inactive comparison group, and one small oral trial in men that measured blood pressure and cholesterol rather than hair.

The risks are modest and mostly avoidable. Skin reactions to the daisy family are the main concern with a leave-on preparation, heavy oiling can block pores along the hairline, and the oral form lowers blood pressure and increases fluid loss enough to matter for anyone already on medication for either. The largest single hazard is not the plant but the supply chain: a substantial share of Ayurvedic products sold online has carried detectable toxic metal.

The evidence base is narrow in who produced it: the one hair study came from a research company working for the Ayurvedic product trade, while the laboratory work is academic. No one has independently pooled the evidence. What is known fits a mild conditioning effect; what is unknown is whether the plant itself accounts for any of it.

Top - Benefits - Risks - Protocol